Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

iologicals SA (GSK) for the development and commercialization of needle-free, patch-based vaccines. Under the terms of the agreement, GSK made an up-front cash contribution of EUR 33.6m (USD 49.4m), in addition to an equity investment of up to EUR 84.0m (USD 123.5m) through staggered share purchases of up to 5% of Intercell, of which 900,000 shares, or 1.9%, have been purchased in December 2009 at a price of EUR 31.21 per share.

With GSK as its future marketing partner, Intercell is pushing its development efforts for the investigational Travelers' Diarrhea (TD) Vaccine Patch towards licensure. The vaccine candidate targets an indication that affects approximately 20 million international travelers annually and for which no vaccine is currently available. The TD Vaccine Patch is presently being investigated in a randomized, placebo-controlled Phase III pivotal efficacy study of 1,800 travelers from Europe to Mexico and Guatemala. In addition, a Phase II placebo-controlled pilot-efficacy trial was launched in 800 subjects from the UK and Germany traveling to India as well as a recently initiated Phase II supportive safety study in healthy U.S. volunteers.

Vaccine Enhancement (VE) Patch - Pandemic Influenza p
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 According to the ... to reshape the look and feel of markets for ... for higher-quality ingredients will push for more branded, science-backed ... have experienced strong market growth in the last decade ... their food and cosmetics to fit a more ‘wellness’ ...
(Date:8/26/2014)... -- NeuroSigma, Inc., a Los Angeles -based ... announced that it has filed a registration statement on ... relating to a proposed initial public offering of its ... and the price range for the proposed offering have ... act as the book-running manager for the proposed offering, ...
(Date:8/26/2014)... argument has just been added to the growing ... as the next big thing in the high-tech ... materials. An international collaboration of researchers led by ... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab) has ... transfer in photo-excited MX2 materials. The recorded charge ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
Breaking Biology Technology:Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Competition for graphene 2Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2
... July 31 Vista Partners announced today,that it ... drug,candidates, which target billion dollar markets, are progressing ... will present Phase 2 results for,Convivia(TM) sometime in ... FDA approval,of Delayed Release (DR) Cysteamine for the ...
... Iceland, July 31 deCODE genetics,Inc. (Nasdaq: DCGN ... quarter,2008 financial results in a press release to be ... market in New York. The company will host a ... and recent,operating highlights on Thursday, August 7, at 8am ...
... 31 InNexus,Biotechnology Inc., (TSX VENTURE: IXS; ... drug development company commercializing the,next generation of ... Linking,(DXL(TM)) technology, will present at IBC,s 13th ... Innovative Therapeutics (DDT) Conference being,held in Boston ...
Cached Biology Technology:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results 2InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2
(Date:8/26/2014)... Scientists succeeded in obtaining an unprecedented view of ... in a range of neurological illnesses, including Alzheimer,s ... injuries associated with stroke. , The team of ... U.S. Department of Energy,s Advanced Photon Source at ... of the intact NMDA (N-methyl, D-aspartate) receptor should ...
(Date:8/26/2014)... While the importance of enteral nutrition (EN), or feeding ... is well understood, underfeeding is still common. A practice ... be interrupted by tests, procedures, or emergencies. Changing to ... volume per day, could reduce underfeeding. , Such a ... according to a quality improvement audit published in the ...
(Date:8/26/2014)... suggests the planet can produce much more land-plant biomass ... grains and other terrestrial plant parts than previously ... Environmental Science and Technology , recalculates the theoretical limit ... much higher than many current estimates allow. , "When ... you have to make some simplifying assumptions," said University ...
Breaking Biology News(10 mins):Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3Study: Earth can sustain more terrestrial plant growth than previously thought 2Study: Earth can sustain more terrestrial plant growth than previously thought 3
... Louis are bringing the minimalist approach to medical ... technology with a smartphone, enabling a compact, mobile ... fits in the palm of a hand. ... of Computer Science and Engineering, and David Zar, ...
... occur under climate change scenarios has led many scientists to ... But a new study in the May issue of ... the types of plants growing in an area could override ... Higuera of Montana State University and his colleagues show that ...
... environmental scientist from the University of East Anglia (UEA) ... contribution to oceanography. Prof Karen Heywood will ... of the European Geophysical Union assembly in Vienna on ... 25 years of successful field work at sea, Prof ...
Cached Biology News:Ultrasound imaging now possible with a smartphone 2Ultrasound imaging now possible with a smartphone 3Plants could override climate change effects on wildfires 2
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
...
... Fixation Buffer, used in conjunction with ... can be used to fix and ... staining of cytokines and other cytoplasmic ... been specially formulated for reducing non-specific ...
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Biology Products: